These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8857336)

  • 1. Mitozantrone-induced onycholysis. A series of five cases.
    Creamer JD; Mortimer PS; Powles TJ
    Clin Exp Dermatol; 1995 Nov; 20(6):459-61. PubMed ID: 8857336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitozantrone-induced onycholysis.
    Speechly-Dick ME; Owen ER
    Lancet; 1988 Jan; 1(8577):113. PubMed ID: 2891948
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitozantrone-induced onycholysis.
    Mitchell PL; Harvey VJ
    Eur J Cancer; 1992; 28(1):243-4. PubMed ID: 1567671
    [No Abstract]   [Full Text] [Related]  

  • 4. Case reports: mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma.
    Freiman A; Bouganim N; O'Brien EA
    J Drugs Dermatol; 2005; 4(4):490-2. PubMed ID: 16004024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mitozantrone and epirubicin in advanced breast cancer.
    Cook AM; Chambers EJ; Rees GJ
    Clin Oncol (R Coll Radiol); 1996; 8(6):363-6. PubMed ID: 8973851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.
    Lawton PA; Spittle MF; Ostrowski MJ; Young T; Madden F; Folkes A; Hill BT; MacRae K
    Clin Oncol (R Coll Radiol); 1993; 5(2):80-4. PubMed ID: 8481365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nail alterations secondary to pactitaxel [corrected] therapy.
    Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
    Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.
    Alimonti A; Nardoni C; Papaldo P; Ferretti G; Caleno MP; Carlini P; Fabi A; Rasio D; Vecchione A; Cognetti F
    Anticancer Res; 2005; 25(5):3531-2. PubMed ID: 16101175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-mitozantrone monoclonal antibody NO-1, protects acute leukaemia cell lines from the cytotoxic effects of mitozantrone.
    Flavell SU; Flavell DJ
    Br J Haematol; 1991 Jul; 78(3):330-3. PubMed ID: 1873218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel).
    Ghetti E; Piraccini BM; Tosti A
    J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):459-60. PubMed ID: 12834462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone.
    Stuart-Harris R; Simes RJ; Coates AS; Raghavan D; Devine R; Tattersall MH
    Eur J Cancer Clin Oncol; 1987 May; 23(5):557-61. PubMed ID: 3653179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic milestones. Novantrone (mitozantrone).
    Cotter FE
    Br J Clin Pract; 1988 May; 42(5):207-9. PubMed ID: 3063315
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography.
    Cassidy J; Merrick MV; Smyth JF; Leonard RC
    Eur J Cancer Clin Oncol; 1988 May; 24(5):935-8. PubMed ID: 3169098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitozantrone.
    Drug Ther Bull; 1986 Sep; 24(18):71-2. PubMed ID: 3757795
    [No Abstract]   [Full Text] [Related]  

  • 15. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot.
    Scotté F; Banu E; Medioni J; Levy E; Ebenezer C; Marsan S; Banu A; Tourani JM; Andrieu JM; Oudard S
    Cancer; 2008 Apr; 112(7):1625-31. PubMed ID: 18286527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
    Hussain S; Anderson DN; Salvatti ME; Adamson B; McManus M; Braverman AS
    Cancer; 2000 May; 88(10):2367-71. PubMed ID: 10820360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eruptive nevi in a patient with metastatic breast cancer.
    Calleja-Algarra A; Aragón-Miguel R; Velasco-Tamariz V; Andrés-Lencina JJ; Prieto Barrios M; Maroñas Jiménez L; Ortiz Romero PL; Monsálvez Honrubia V
    Int J Dermatol; 2017 Dec; 56(12):1508-1509. PubMed ID: 28960262
    [No Abstract]   [Full Text] [Related]  

  • 19. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration.
    Roh MR; Cho JY; Lew W
    Yonsei Med J; 2007 Feb; 48(1):124-6. PubMed ID: 17326255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
    Pusztai L; Holmes FA; Fraschini G; Hortobagyi GN
    Cancer Chemother Pharmacol; 1999; 43(1):86-91. PubMed ID: 9923546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.